Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Interstitial lung disease or pneumonitis ... Currently, ENHERTU is approved in over 75 countries for patients with HER2 low metastatic breast cancer who have received prior systemic therapy ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Two impressive studies in lung cancer and another in breast ... which could extend the reach of antibody-drug conjugate (ADC) Enhertu in breast cancer with even lower levels of biomarker HER2.

lung, and other cancers in adults. For a doctor to prescribe Enhertu, the cancer must involve HER2 in some way. Each of these cancers also has other specific criteria for treatment with Enhertu ...

Interstitial lung disease or pneumonitis was reported in 11.3% of patients treated with ENHERTU, with most cases being low grade. Currently, ENHERTU is approved in over 75 countries for patients with ...

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy ... including interstitial lung disease (ILD), that may be more significant than is typically ...